Valuation: Emergent BioSolutions Inc.

Market Cap 298M 270M 250M 225M 424M 28.07B 439M 3B 1.19B 14.99B 1.12B 1.09B 47.6B P/E 2026 *
-1.27x
P/E 2027 * 81.1x
Enterprise Value 668M 605M 560M 505M 952M 62.97B 985M 6.72B 2.67B 33.64B 2.51B 2.45B 107B EV / Sales 2026 *
1.03x
EV / Sales 2027 * 0.86x
Free-Float
79.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.70%
1 week-4.46%
Current month-14.98%
1 month-16.21%
3 months+28.95%
6 months-30.49%
Current year-53.16%
1 week 5.76
Extreme 5.76
6.23
1 month 5.51
Extreme 5.51
7.3
Current year 4.36
Extreme 4.36
14.06
1 year 4.36
Extreme 4.36
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
52.28
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 21/02/2024
Director of Finance/CFO 62 26/03/2018
Compliance Officer 55 01/03/2020
Director TitleAgeSince
Chairman 82 01/04/2022
Director/Board Member 70 01/01/2005
Director/Board Member 77 01/10/2016
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Sell

Director

-17,800 0.0347%
01/10/26 Sell

Executive/Senior Manager

-3,000 0.0059%
05/08/26 Other

Executive/Senior Manager

455,311 0.8824%
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-4.46%-43.90%+218.13% 298M
+1.26%+6.61%+41.12%+135.59% 1,286B
+0.79%+3.45%+46.35%+93.56% 688B
+0.20%+1.28%+27.01%+112.80% 521B
-0.44%+3.69%+39.60%+69.51% 386B
+0.55%+0.70%+59.00%+44.20% 364B
-0.12%+0.74%+26.78%+58.43% 302B
+0.37%+0.37%+3.62%+36.44% 287B
-0.30%+1.14%+38.59%+74.61% 252B
+0.08%+0.71%+34.25%+124.32% 208B
Average +0.07%+1.94%+27.24%+96.76% 429B
Weighted average by Cap. +0.54%+3.26%+37.62%+96.24%

Financials

2026 *2027 *
Net sales 647M 586M 542M 489M 922M 60.98B 954M 6.51B 2.58B 32.58B 2.43B 2.38B 103B 703M 637M 590M 532M 1B 66.32B 1.04B 7.08B 2.81B 35.42B 2.64B 2.58B 112B
Net income -237M -215M -199M -179M -338M -22.38B -350M -2.39B -948M -11.95B -891M -872M -37.94B 3.83M 3.47M 3.21M 2.89M 5.45M 361M 5.64M 38.52M 15.28M 193M 14.36M 14.05M 612M
Net Debt 370M 335M 310M 280M 528M 34.9B 546M 3.73B 1.48B 18.64B 1.39B 1.36B 59.18B 309M 280M 259M 234M 440M 29.12B 456M 3.11B 1.23B 15.56B 1.16B 1.13B 49.38B
Projected Income Statement - Annual - Emergent BioSolutions Inc.
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
13/11/26 $5.790 -1.70% 787,177
12/11/26 $5.890 -2.48% 1,003,009
11/11/26 $6.040 -0.17% 516,260
10/11/26 $6.050 -0.82% 654,434
09/11/26 $6.100 +0.66% 846,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Emergent BioSolutions Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.790USD
Average target price
10.00USD
Spread / Average Target
+72.71%